The Biotech Growth Trust (BIOG) aims to generate long-term capital growth from a concentrated portfolio of global biotech companies. It is jointly managed by Richard Klemm and Geoff Hsu of OrbiMed Capital, who are positive on the outlook for the biotech industry due to a favourable regulatory backdrop, continued industry innovation, an anticipated uptick in M&A activity and reasonable company valuations. The trust is benchmarked against the NASDAQ Biotech index, which it has outperformed
22 Feb 2018
Positive outlook for the biotech sector
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive outlook for the biotech sector
Biotech Growth Trust PLC (BIOG:LON) | 988 -19.8 (-0.2%) | Mkt Cap: 332.1m
- Published:
22 Feb 2018 -
Author:
Mel Jenner -
Pages:
8
The Biotech Growth Trust (BIOG) aims to generate long-term capital growth from a concentrated portfolio of global biotech companies. It is jointly managed by Richard Klemm and Geoff Hsu of OrbiMed Capital, who are positive on the outlook for the biotech industry due to a favourable regulatory backdrop, continued industry innovation, an anticipated uptick in M&A activity and reasonable company valuations. The trust is benchmarked against the NASDAQ Biotech index, which it has outperformed